Nice | Idelalisib for treating chronic lymphocytic leukaemia

15th February 2016 by Louise Hudman

Nice | Idelalisib for treating chronic lymphocytic leukaemia

This is a new guideline from NICE on idelalisib use in chronic lymphocytic leukaemia. Idelalisib is likely to be secondary care prescribed, but I felt it was worthwhile knowing about as it is a new type of drug and we will probably see patients on it.

Idelalisib is an oral drug and will be used in combination with rituximab infusions. It is a ‘first-in-class’ drug which inhibits enzymes involved in cell proliferation, death and migration.


Among other side-effects, it can raise transaminases, triglycerides and can cause neutropenia.

Read for free

Sign up to access everything.

Three-month free trial


Already a member? Login to view this content.


"I have been working with NASGP as the main source of income since graduating. I can't recommend them more highly for newly-graduated GPs. They helped me with setting my terms and conditions and they even arranged a tutorial session about EMIS, as the system was new to me.

LocumDeck is a great help when it comes to organising sessions, pension forms and invoices for tax purposes.

NASGP was particularly supportive during the Covid-19 period. It recognised the effect it had on locum work, temporarily waived the already small fee on sessions and were keen on getting the members together in regular video meetings.

I'm a satisfied member of NASGP. "

Dr Nazar Ahmed

Dr Nazar Ahmed

See the full list of features within our NASGP membership plans